WO2005010152A3 - Human mast cell-expressed membrane protein - Google Patents

Human mast cell-expressed membrane protein Download PDF

Info

Publication number
WO2005010152A3
WO2005010152A3 PCT/US2004/020296 US2004020296W WO2005010152A3 WO 2005010152 A3 WO2005010152 A3 WO 2005010152A3 US 2004020296 W US2004020296 W US 2004020296W WO 2005010152 A3 WO2005010152 A3 WO 2005010152A3
Authority
WO
WIPO (PCT)
Prior art keywords
allergic
mast cell
membrane protein
human mast
gpr91
Prior art date
Application number
PCT/US2004/020296
Other languages
French (fr)
Other versions
WO2005010152A2 (en
Inventor
Kang Li
Shen-Wu Wang
Guanghui Hu
Zhengbin Yao
Original Assignee
Tanox Inc
Kang Li
Shen-Wu Wang
Guanghui Hu
Zhengbin Yao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc, Kang Li, Shen-Wu Wang, Guanghui Hu, Zhengbin Yao filed Critical Tanox Inc
Priority to JP2006517621A priority Critical patent/JP2007526747A/en
Priority to AU2004259399A priority patent/AU2004259399A1/en
Priority to EP04777035A priority patent/EP1648488A4/en
Priority to CA002531073A priority patent/CA2531073A1/en
Publication of WO2005010152A2 publication Critical patent/WO2005010152A2/en
Publication of WO2005010152A3 publication Critical patent/WO2005010152A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)

Abstract

The present invention relates to GPR91, a purinergic receptor-like polypeptide, its expression in mast cells, and its use in the diagnosis and/or treatment of mast cell mediated diseases, including allergic and nonallergic asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, anaphylaxis, allergic gastrointestinal disease, atopic dermatitis, rheumatoid arthritis, and other allergic, autoimmune and inflammatory diseases. The invention also includes methods of screening of agonists and/or antagonists of the GPR91 receptor.
PCT/US2004/020296 2003-06-27 2004-06-25 Human mast cell-expressed membrane protein WO2005010152A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2006517621A JP2007526747A (en) 2003-06-27 2004-06-25 Human mast cell expression membrane protein
AU2004259399A AU2004259399A1 (en) 2003-06-27 2004-06-25 Human mast cell-expressed membrane protein
EP04777035A EP1648488A4 (en) 2003-06-27 2004-06-25 Human mast cell-expressed membrane protein
CA002531073A CA2531073A1 (en) 2003-06-27 2004-06-25 Human mast cell-expressed membrane protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48336003P 2003-06-27 2003-06-27
US60/483,360 2003-06-27

Publications (2)

Publication Number Publication Date
WO2005010152A2 WO2005010152A2 (en) 2005-02-03
WO2005010152A3 true WO2005010152A3 (en) 2005-05-12

Family

ID=34102650

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/020296 WO2005010152A2 (en) 2003-06-27 2004-06-25 Human mast cell-expressed membrane protein

Country Status (6)

Country Link
EP (1) EP1648488A4 (en)
JP (1) JP2007526747A (en)
CN (1) CN1812803A (en)
AU (1) AU2004259399A1 (en)
CA (1) CA2531073A1 (en)
WO (1) WO2005010152A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0508990D0 (en) * 2005-05-03 2005-06-08 Novartis Ag Organic compounds
WO2009011885A1 (en) * 2007-07-18 2009-01-22 Arena Pharmaceuticals, Inc. Modulators of hematopoiesis
KR101524653B1 (en) * 2012-10-26 2015-06-03 한국생명공학연구원 A method for identifying the modulators of GPR43
CN108546751A (en) * 2018-04-20 2018-09-18 中国科学院武汉病毒研究所 Application of the Protein S as biomarker in preparing asthma disease diagnosis and prognosis effect appraisal reagent
CN111781369A (en) * 2019-04-03 2020-10-16 复旦大学 Application of GPR-91 succinate receptor as molecular target in pharmacy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000031258A2 (en) * 1998-11-20 2000-06-02 Arena Pharmaceuticals, Inc. Human orphan g protein-coupled receptors
US20020086822A1 (en) * 2000-01-31 2002-07-04 Rosen Craig A. Nucleic acids, proteins, and antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001268471A1 (en) * 2000-06-16 2002-01-02 Incyte Genomics, Inc. G-protein coupled receptors
US7157244B2 (en) * 2001-01-17 2007-01-02 Schering Corporation Adenosine receptor
WO2005050220A1 (en) * 2003-10-31 2005-06-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 91 (gpr91)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000031258A2 (en) * 1998-11-20 2000-06-02 Arena Pharmaceuticals, Inc. Human orphan g protein-coupled receptors
US20020086822A1 (en) * 2000-01-31 2002-07-04 Rosen Craig A. Nucleic acids, proteins, and antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP1648488A4 *
WITTENBERGER ET AL.: "An expressed sequence tag (EST) data mining strategy succeeding in the discovery of new G-protein coupled receptors", JOURNAL OF MOLECULAR BIOLOGY, vol. 307, 2001, pages 799 - 813, XP002985502 *

Also Published As

Publication number Publication date
EP1648488A2 (en) 2006-04-26
AU2004259399A1 (en) 2005-02-03
WO2005010152A2 (en) 2005-02-03
JP2007526747A (en) 2007-09-20
EP1648488A4 (en) 2007-01-24
CA2531073A1 (en) 2005-02-03
CN1812803A (en) 2006-08-02

Similar Documents

Publication Publication Date Title
MY144906A (en) Human antibodies against il13 and therapeutic uses
WO2004011427A3 (en) Substituted benzanilides as modulators of the ccr5 receptor
WO2004078938A3 (en) Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2009074634A3 (en) Polypeptides, antibody variable domains & antagonists
EP2322553A3 (en) Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
WO2005010152A3 (en) Human mast cell-expressed membrane protein
HRP20140888T1 (en) Human monoclonal antibodies against human il-4
WO2007008708A3 (en) Methods of predicting hyp-glycosylation sites for proteins expressed and secreted in plant cells, and related methods and products
WO2005068655A3 (en) Methods of assessing a tissue inflammatory response using expression profiles of endothelial cells
WO2001068705A3 (en) Il-17 receptor like molecules and uses thereof
WO2007121495A3 (en) Method for diagnosing cardiovascular diseases
WO2004081043A3 (en) Baff mutants with at least one amino acid substitution and methods of their production
WO2003046147A3 (en) Novel human g-protein coupled receptor, hgprbmy31, and variants and methods of use thereof
WO2009145606A8 (en) Method for the production of proteins or protein fragments
Lin et al. Cytologic distinctions between clinical groups using curette-probe compared to cytology brush
Gomułka et al. Peripheral blood eosinophils priming and in vitro VEGF stimulation in asthmatics
CN217558229U (en) Suspension door and door row bottom beam connecting and fixing assembly thereof
WO2006052489A3 (en) T cell proteins and nucleotides encoding the same
Yagawa Finite Element Dual Analysis for Piezoelectric Crack
Crull et al. T Cell Inflammatory Pathways In Acute Respiratory Distress Syndrome (ARDS)
Cardenes et al. Deficiencies in mesenchymal stem cells from idiopathic pulmonary fibrosis patients result in lower capacity to protect the lung from injury
Pasqui et al. Occupational therapy in rheumatoid arthritis: short term prospective study in patients treated with anti-TNF-alpha drugs
Rutten et al. Body Compositional Shift in COPD Patients Stratified for BMI.
MARHL Acute Systemic Inflammation in Obese and Hypertensive Patients Following Full-Mouth versus Quadrant Non-Surgical Treatment of Periodontitis
DE60329492D1 (en) PRODUCTION OF RECOMBINANT FRAGMENTS FROM THE MUSCLE ACETYLCHOLINE RECEPTOR AND THEIR USE FOR EX VIVO IMMUNABSORPTION OF ANTI-ACH RECEPTOR ANTIBODIES IN PATIENTS WITH MYASTHENIA

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004259399

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2531073

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006517621

Country of ref document: JP

Ref document number: 20048179533

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2004259399

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004777035

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004777035

Country of ref document: EP